GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020
July 24 2020 - 9:15AM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will
host a conference call and webcast to report its second quarter
financial results on Friday, July 31, 2020, at 8:30 a.m. ET.
The dial-in number for the conference call is (844) 413-7154 for
domestic participants or (216) 562-0466 for international
participants, with participant code 1677593. Participants are
encouraged to connect 15 minutes in advance of the call to ensure
that all callers are able to connect. A webcast replay will be
available via the “Investors” tab on the GlycoMimetics website for
30 days following the call. A dial-in phone replay will be
available for 24 hours after the close of the call by dialing
(855)-859-2056 for domestic participants and (404) 537-3406 for
international participants, participant code 1677593.
About GlycoMimetics, Inc.
GlycoMimetics is a biotechnology company with two late-stage
clinical development programs and a pipeline of novel glycomimetic
drugs, all designed to address unmet medical needs resulting from
diseases in which carbohydrate biology plays a key role.
GlycoMimetics' drug candidate, uproleselan, an E-selectin
antagonist, was evaluated in a Phase 1/2 clinical trial as a
potential treatment for AML and is being evaluated across a range
of patient populations including a Company-sponsored Phase 3 trial
in relapsed/refractory AML under breakthrough therapy designation.
Rivipansel, a pan-selectin antagonist, is being explored for use in
treatment of acute VOC in SCD. GlycoMimetics has also completed a
Phase 1 clinical trial with another wholly-owned drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics
is located in Rockville, MD in the BioHealth Capital Region. Learn
more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the Company’s strategy and the clinical development and potential
benefits and impact of its drug candidates. These forward-looking
statements include those relating to the planned clinical
development of the Company’s product candidates, including
expectations with regard to the enrollment of patients in its
ongoing Phase 3 clinical trial, and its other plans for its current
cash resources. Actual results may differ materially from those in
these forward-looking statements. For a further description of the
risks associated with these statements, as well as other risks
facing GlycoMimetics, please see the risk factors described in the
Company’s annual report on Form 10-K filed with the U.S. Securities
and Exchange Commission (SEC) on February 28, 2020, and other
filings GlycoMimetics makes with the SEC from time to time.
Forward-looking statements speak only as of the date of this
release, and GlycoMimetics undertakes no obligation to update or
revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200724005283/en/
Investor Contact: Shari Annes Phone: 650-888-0902 Email:
sannes@annesassociates.com
Media Contact: Jamie Lacey-Moreira Phone: 410-299-3310 Email:
jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024